Neuren Pharmaceuticals (OTCMKTS:NURPF) vs. ArriVent BioPharma (NASDAQ:AVBP) Financial Analysis

Neuren Pharmaceuticals (OTCMKTS:NURPF) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Neuren Pharmaceuticals and ArriVent BioPharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuren Pharmaceuticals	N/A	N/A	N/A	C($0.01)	-1,734.12
ArriVent BioPharma	N/A	N/A	-$166.31 million	($3.62)	-8.29

Neuren Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuren Pharmaceuticals and ArriVent BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuren Pharmaceuticals	0	0	0	0	0.00
ArriVent BioPharma	1	1	8	0	2.70

ArriVent BioPharma has a consensus target price of $44.86, suggesting a potential upside of 49.52%. Given ArriVent BioPharma’s stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Neuren Pharmaceuticals.

Insider & Institutional Ownership

1.7% of Neuren Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Neuren Pharmaceuticals and ArriVent BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuren Pharmaceuticals	N/A	N/A	N/A
ArriVent BioPharma	N/A	-50.26%	-46.66%

Summary

ArriVent BioPharma beats Neuren Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

About ArriVent BioPharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.